Research programme: adipose mesenchymal stem cell derived therapeutic factor concentrates - Theratome Bio/Cytovance Biologics

Drug Profile

Research programme: adipose mesenchymal stem cell derived therapeutic factor concentrates - Theratome Bio/Cytovance Biologics

Alternative Names: NFx-101

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroFx
  • Developer Cytovance Biologics; Theratome Bio
  • Class Stem cell factors
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Macrophage inhibitors; Neurogenesis stimulants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries; Neurological disorders

Most Recent Events

  • 12 Aug 2015 Preclinical trials in Brain injuries in USA (Parenteral) prior to August 2015
  • 12 Aug 2015 Preclinical trials in Neurological disorders in USA (Parenteral) prior to August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top